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391Abstracts
agement in ambulatory care setting is suboptimal as less than
1% of the visits were diagnosed with dementia/AD and only 
half of them had CEA therapy. Additionally our ﬁndings demon-
strate that physicians specialized in psychiatry and neurology
predominantly provide ambulatory care services for dementia
patients.
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OBJECTIVES: Analysis was conducted to estimate annual direct
medical costs for community dwelling persons with dementia
and to determine the proportion of costs in various categories
paid by various payers. METHODS: Retrospective analysis was
conducted of the 2001 Medical Expenditure Panel Survey. The
survey provided data from a sample of 33,556 respondents and
is representative of the civilian non-institutionalized population
of the United States. Dementia patients were identiﬁed using
ICD-9-CM codes. For each patient with dementia, one patient
without dementia was randomly selected matched on age,
gender, race, and number of medical conditions. Medical care
costs for each service component were calculated and compared.
The proportion of medical care costs paid by each payer was 
calculated for dementia patients. Sample estimates were pro-
jected to the population and standard errors were calculated
using the Taylor expansion method. RESULTS: In 2001, the
mean total health care expenditure per patient with dementia
was $12,310, while the mean total expenditure for a matched
patient without dementia was $7300. Among dementia patients,
the highest proportion of costs were for inpatient hospital stays
at $4709 (SE = $727), followed by home health care at $3703
($450). Patients with dementia had a signiﬁcantly higher mean
number of home health provider days at 74.6 days (10.5), com-
pared to patients without dementia, 3.8 days (1.0). The major
sources of payments for health care expenditures of dementia
patients were Medicare (38.3%) and out-of-pocket payments
(32.6%). Approximately 62% of prescription drug expenditures
among dementia patients were paid out-of-pocket. Incremental
costs per patient with dementia were $5010, or a total cost 
of $8.3 billion attributable to dementia in community dwelling
patients. CONCLUSIONS: Community dwelling dementia
patients cost approximately 1.7 times more than similar patients
without dementia. A high proportion of total expenditures, espe-
cially prescription drug expenditures among dementia patients
were paid out-of-pocket.
PMH22
PREDICTORS OF HEALTH RELATED QUALITY 
OF LIFE AMONG DEMENTIA CAREGIVERS: A 
LONGITUDINAL EXAMINATION
Madan A1, Clay O1, Kilgore M1, Roth D1, Mittelman M2
1University of Alabama at Birmingham, Birmingham, AL, USA;
2New York University School of Medicine, New York, NY, USA
OBJECTIVES: Poorer health related quality of life (HRQOL)
has been observed among dementia caregivers relative to the
general population. However, the temporal stability of and
factors associated with caregiver HRQOL have been little
studied. METHODS: Dementia caregivers were randomized to
one of two treatment arms: a multi-component, psychosocial
intervention aimed at increasing social support (n = 69) or to 
a usual care, control group (n = 65). Caregiver HRQOL was
assessed over a two-year period using a Visual Analogue Scale
(VAS), the Health Utilities Index Mark III (HUI), and the SF-36
(physical health [PCS] and mental health [MCS] summary
scores). Patient-speciﬁc and caregiver-speciﬁc data were collected
every four-months during the ﬁrst year and every six-months
thereafter. A step-wise, mixed-model approach was employed to
assess the association of treatment-, patient-, and caregiver-
speciﬁc variables to caregiver HRQOL. RESULTS: None of the
patient demographic variables was associated with caregiver
HRQOL. Caregiver gender, health status and depression along
with patient dementia severity were all inversely associated with
the VAS, but patient nursing home placement was positively
associated. Caregiver age, health status and depression were
inversely associated with the HUI. Dementia severity and care-
giver depression were inversely associated with the MCS. Care-
giver age and health status were inversely associated with the
PCS. Time since enrollment was positively associated with care-
giver MCS but inversely associated with caregiver PCS; time was
not signiﬁcantly associated with the VAS or HUI. CONCLU-
SIONS: A number of patient-, caregiver-, and time-related vari-
ables were differentially associated with the disparate measures
of HRQOL. Caregiver depression and health status are consis-
tently associated with poorer HRQOL regardless of instrument
used to measure it. The VAS and HUI appear to be more stable
measures of HRQOL than the summary scores from the SF-36.
However, small sample size and methodological limitations
temper these ﬁndings.
PMH23
ASSESSING VENLAFAXINE, SERTRALINE, OR PLACEBO
TREATMENT ON IMPROVEMENT IN GENERAL LIFE
FUNCTIONING AMONG DEPRESSED PATIENTS
Zhang HF, Khandker R
Wyeth Research, Collegeville, PA, USA
OBJECTIVE: This analysis was designed to compare improve-
ments in health-related quality of life (HRQoL) measured by the
General Life Functioning scale (GLF) in patients with major
depressive disorder (MDD) treated with venlafaxine extended
release (XR), sertraline, or placebo. METHODS: Data were
pooled from two identical multicenter, randomized, double-
blind, placebo-controlled studies of ﬂexible-dose venlafaxine XR
(37.5–300mg/day) and sertraline (50–200mg/day) in 10-week
treatment of DSM-IV MDD (N = 1352). Average per-item score
(ranging from one being “best” and six being “worst”) of overall
GLF and its three subscales (well-being, coping, and closeness)
were used to assess functioning. Improvement was measured by
reduction from baseline score at the end of the study, and was
analyzed using ANCOVA controlling for study center and base-
line values. In addition, the overall trend of weekly scores during
treatment was evaluated using repeated measures mixed model.
RESULTS: At baseline, GLF per-item score had a median of four.
At the end of study, venlafaxine XR was associated with signif-
icant (P < 0.0001) improvement (as measured by per-item score
reduction from baseline) compared with placebo on GLF total
score (1.0 vs. 0.6) and all three subscales: well-being (1.2 vs. 0.7),
coping (1.0 vs. 0.6), and closeness (0.8 vs. 0.4). The weekly
trends of total and subscale scores were also signiﬁcantly better
for venlafaxine XR compared with placebo (all P < 0.0025). Ser-
traline/placebo differences on all measures were also statistically
signiﬁcant but numerically smaller. CONCLUSION: Venlafaxine
XR and sertraline treatment were associated with signiﬁcant
improvement on HRQoL measured by GLF in depressed
patients.
